Literature DB >> 11255826

"Be smart, be safe, be sure". The revised Pregnancy Prevention Program for women on isotretinoin.

S E Perlman1, E E Leach, L Dominguez, A M Ruszkowski, S J Rudy.   

Abstract

OBJECTIVES: After studying the information in this article, the reader should be able to: 1. Describe the purpose of the pregnancy prevention program. 2. Discuss the five most common reasons for unintended pregnancy. 3. List the components of the expanded pregnancy prevention program. Preventing unintended pregnancy is currently an unsolved problem in the United States, especially among teens. However, successful programs to minimize unintended pregnancy do exist and can serve as a model for other efforts. One such program is the Pregnancy Prevention Program, for use when prescribing isotretinoin to women with childbearing potential. Isotretinoin is a known teratogen and is prescribed disproportionately to teens, who are at higher risk of unintended pregnancy. The program has shown impressive effectiveness despite these handicaps, but since exposure to isotretinoin is so harmful to the fetus and some women still become pregnant while taking the drug, the program has been revised to reduce the failure rate further.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11255826

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  3 in total

Review 1.  Preconception healthcare and congenital disorders: systematic review of the effectiveness of preconception care programs in the prevention of congenital disorders.

Authors:  Geordan D Shannon; Corinna Alberg; Luis Nacul; Nora Pashayan
Journal:  Matern Child Health J       Date:  2014-08

Review 2.  Preconception care for improving perinatal outcomes: the time to act.

Authors:  Hani K Atrash; Kay Johnson; Myron Adams; José F Cordero; Jennifer Howse
Journal:  Matern Child Health J       Date:  2006-06-14

Review 3.  What is the best approach to reducing birth defects associated with isotretinoin?

Authors:  Lorien Abroms; Edward Maibach; Katherine Lyon-Daniel; Steven R Feldman
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.